Summary Regeneron Pharmaceuticals has much money and the debt ratio is very lower. The firm’ financial performance fluctuate substantially, which trigger the fluctuation of the stock price. The company value the price of stock. We reckon that $734 per share is a good buy point ,or market capitalization reach $80 billion.   Asset structure analysis…

Summary Gilead Sciences, inc. is a cash cow. We reckon that $80 billion market value for the company is reasonable . The acquisitions is an expansion model, which is unpredictable. It hit the peak of debt. Gilead Sciences, inc. is a biopharmaceutical company that have two reportable business: product sales ,and royalty, contract and other. …